Home / Market News / $INSM
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

H.C. Wainwright Assumes Coverage of Insmed with Buy Rating

Nov 4, 2026, 11:03 PM UTC · Primary ticker $INSM

H.C. Wainwright & Co. initiated coverage of Insmed Incorporated with a 'Buy' rating and a $220 price target, representing a substantial upside from its recent closing price. This positive analyst coverage could generate increased investor interest and potentially drive the stock price higher in the short term.

H.C. Wainwright & Co. has assumed coverage of Insmed Incorporated, assigning a 'Buy' rating and a price target of $220 per share. This represents a significant premium over the stock's closing price of $104.44 on November 3, 2026. This analyst initiation is a positive development for Insmed, as it signals increased institutional confidence and could attract new investors. For traders, this presents a potential short-term buying opportunity as the market reacts to the bullish outlook, though long-term performance will depend on the company's fundamental execution. The key opportunity lies in the substantial upside projected by H.C. Wainwright, but the risk remains that the market may not fully embrace this valuation or that future company performance could deviate from expectations.

$INSM positive New 'Buy' rating and high price target
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.